Oxidative modification of proteins in pediatric cystic fibrosis with bacterial infections

Oxidative Medicine and Cellular Longevity

Volumn 2014, Issue , 2014, Pages

  Sadowska Bartosz, Izabela ^a   Galiniak, Sabina ^a   Bartosz, Grzegorz ^a,b   Rachel, Marta ^a  

^a UNIVERSITY OF RZESZÓW   (Poland)

^b UNIVERSITY OF LODZ   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIA; NITRIC OXIDE;

ANTIOXIDANT ENZYME; BACTERIAL INFECTIONS; CHRONIC OXIDATIVE STRESS; GLUTATHIONE-S-TRANSFERASE; OXIDATIVE MODIFICATION; PROTEIN CARBONYLS; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

PROTEINS;

GLUTATHIONE TRANSFERASE; KYNURENINE; NITRIC OXIDE; PLASMA PROTEIN;

ADOLESCENT; BACTERIAL INFECTIONS; CHEMISTRY; CHILD; COMPLICATION; CYSTIC FIBROSIS; CYTOLOGY; ENZYMOLOGY; ERYTHROCYTE; FEMALE; HUMAN; MALE; METABOLISM; MICROBIOLOGY; OXIDATIVE STRESS; PATHOGENICITY; PROTEIN CARBONYLATION; PSEUDOMONAS AERUGINOSA; RESPIRATORY SYSTEM; STAPHYLOCOCCUS AUREUS;

ADOLESCENT; BACTERIAL INFECTIONS; BLOOD PROTEINS; CHILD; CYSTIC FIBROSIS; ERYTHROCYTES; FEMALE; GLUTATHIONE TRANSFERASE; HUMANS; KYNURENINE; MALE; NITRIC OXIDE; OXIDATIVE STRESS; PROTEIN CARBONYLATION; PSEUDOMONAS AERUGINOSA; RESPIRATORY SYSTEM; STAPHYLOCOCCUS AUREUS;

EID: 84899546562     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2014/389629     Document Type: Article

References (50)

1. Lyczak J. B., Cannon C. L., Pier G. B., Lung infections associated with cystic fibrosis. Clinical Microbiology Reviews 2002 15 2 194 222 2-s2.0-0036225688 10.1128/CMR.15.2.194-222.2002 (Pubitemid 34303763)
2. Chmiel J. F., Konstan M. W., Elborn J. S., Antibiotic and anti-inflammatory therapies for cystic fibrosis. Cold Spring Harbor Perspectives in Medicine 2013 3 10 a009779
3. Dubin P. J., Kolls J. K., IL-23 mediates inflammatory responses to mucoid Pseudomonas aeruginosa lung infection in mice. American Journal of Physiology 2007 292 2 L519 L528 2-s2.0-33847043963 10.1152/ajplung.00312.2006
4. Geller D. E., Aerosol antibiotics in cystic fibrosis. Respiratory Care 2009 54 5 658 669 2-s2.0-66849142486 10.4187/aarc0537
5. Usher L. R., Lawson R. A., Geary I., Taylor C. J., Bingle C. D., Taylor G. W., Whyte M. K. B., Induction of neutrophil apoptosis by the Pseudomonas aeruginosa exotoxin pyocyanin: a potential mechanism of persistent infection. Journal of Immunology 2002 168 4 1861 1868 2-s2.0-0037083467 (Pubitemid 34135787)
6. Wong J. K., Ranganathan S. C., Hart E., Staphylococcus aureus in early cystic fibrosis lung disease. Pediatric Pulmonology 2013
7. Rottner M., Tual-Chalot S., Mostefai H. A., Andriantsitohaina R., Freyssinet J.-M., Martínez M. C., Increased oxidative stress induces apoptosis in human cystic fibrosis cells. PLoS ONE 2011 6 9 2-s2.0-80052612789 10.1371/journal.pone.0024880 e24880
8. Lezo A., Biasi F., Massarenti P., Oxidative stress in stable cystic fibrosis patients: do we need higher antioxidant plasma levels? Journal of Cystic Fibrosis 2013 12 35 41
9. Back E. I., Frindt C., Nohr D., Frank J., Ziebach R., Stern M., Ranke M., Biesalski H. K., Antioxidant deficiency in cystic fibrosis: when is the right time to take action? American Journal of Clinical Nutrition 2004 80 2 374 384 2-s2.0-4344627804 (Pubitemid 41080011)
10. Sadowska-Woda I., Rachel M., Pazdan J., Bieszczad-Bedrejczuk E., Pawliszak K., Nutritional supplement attenuates selected oxidative stress markers in pediatric patients with cystic fibrosis. Nutrition Research 2011 31 7 509 518 2-s2.0-80051594020 10.1016/j.nutres.2011.07.002
11. Brown R. K., Kelly F. J., Evidence for increased oxidative damage in patients with cystic fibrosis. Pediatric Research 1994 36 4 487 493 2-s2.0-0027937417 (Pubitemid 24289786)
12. Davies M. J., The oxidative environment and protein damage. Biochimica et Biophysica Acta 2005 1703 2 93 109 2-s2.0-12844278044 10.1016/j.bbapap.2004.08. 007 (Pubitemid 40170433)
13. Arif B., Ashraf J. M., Moinuddin A. J., Structural and immunological characterization of Amadori-rich human serum albumin: role in diabetes mellitus. Archives of Biochemistry and Biophysics 2012 522 17 25
14. Marta K., Tomáš Z., Petr P., Pavel Š., Martin B., Jiřina S., Květa P., Rosemarie K.-E., Advanced glycation end-products in patients with chronic alcohol misuse. Alcohol and Alcoholism 2004 39 4 316 320 2-s2.0-3242809104 10.1093/alcalc/agh058 (Pubitemid 38976471)
15. Witko-Sarsat V., Friedlander M., Capeillère-Blandin C., Nguyen-Khoa T., Nguyen A. T., Zingraff J., Jungers P., Descamps-Latscha B., Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney International 1996 49 5 1304 1313 2-s2.0-0029948839 (Pubitemid 26166404)
16. Robaszkiewicz A., Bartosz G., Soszyński M., N-chloroamino acids cause oxidative protein modifications in the erythrocyte membrane. Mechanisms of Ageing and Development 2008 129 10 572 579 2-s2.0-54249090219 10.1016/j.mad.2008.05.007
17. Valko M., Leibfritz D., Moncol J., Cronin M. T. D., Mazur M., Telser J., Free radicals and antioxidants in normal physiological functions and human disease. International Journal of Biochemistry and Cell Biology 2007 39 1 44 84 2-s2.0-33749986298 10.1016/j.biocel.2006.07.001 (Pubitemid 44566469)
18. Habig W. H., Pabst M. J., Jakoby W. B., Glutathione S transferases. The first enzymatic step in mercapturic acid formation. Journal of Biological Chemistry 1974 249 22 7130 7139 2-s2.0-0016275313
19. Dweik R. A., Boggs P. B., Erzurum S. C., Irvin C. G., Leigh M. W., Lundberg J. O., Olin A.-C., Plummer A. L., Taylor D. R., An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. American Journal of Respiratory and Critical Care Medicine 2011 184 5 602 615 2-s2.0-80052438246 10.1164/rccm.9120-11ST
20. NCCLS, Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. Approved Standard, 6th Edition. NCCLS document M7-A6, NCCLS
21. Scott-Thomas A. J., Syhre M., Pattemore P. K., Epton M., Laing R., Pearson J., Chambers S. T., 2-Aminoacetophenone as a potential breath biomarker for Pseudomonas aeruginosa in the cystic fibrosis lung. BMC Pulmonary Medicine 2010 10, article 56 2-s2.0-78049356367 10.1186/1471-2466-10-56
22. Tramper-Stranders G. A., Wolfs T. F. W., Fleer A., Kimpen J. L. L., Van Der Ent C. K., Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function. Pediatric Infectious Disease Journal 2007 26 1 8 12 2-s2.0-33845975311 10.1097/01.inf.0000247109.44249.ac (Pubitemid 46045744)
23. Reznick A. Z., Packer L., Oxidative damage to proteins: spectrophotometric method for carbonyl assay. Methods in Enzymology 1994 233 357 363 2-s2.0-0028239163 10.1016/S0076-6879(94)33041-7
24. Henle T., Deppisch R., Beck W., Hergesell O., Hänsch G. M., Ritz E., Advanced glycated end-products (AGE) during haemodialysis treatment: discrepant results with different methodologies reflecting the heterogeneity of AGE compounds. Nephrology Dialysis Transplantation 1999 14 8 1968 1975 2-s2.0-0032803735 10.1093/ndt/14.8.1968 (Pubitemid 29358896)
25. Münch G., Keis R., Weßels A., Riederer P., Bahner U., Heidland A., Niwa T., Lemke H.-D., Schinzel R., Determination of advanced glycation end products in serum by fluorescence spectroscopy and competitive ELISA1. European Journal of Clinical Chemistry and Clinical Biochemistry 1997 35 9 669 677 2-s2.0-0030698699
26. Lowry O. H., Rosebrough N. J., Farr A. L., Randall R. J., Protein measurement with the Folin phenol reagent. The Journal of Biological Chemistry 1951 193 1 265 275 2-s2.0-71849104860
27. Johnson R. N., Metcalf P. A., Baker J. R., Fructosamine: a new approach to the estimation of serum glycosylprotein. An index of diabetic control. Clinica Chimica Acta 1983 127 1 87 95 2-s2.0-0020655989 10.1016/0009-8981(83) 90078-5 (Pubitemid 13168108)
28. Mironova R., Niwa T., Handzhiyski Y., Sredovska A., Ivanov I., Evidence for non-enzymatic glycosylation of Escherichia coli chromosomal DNA. Molecular Microbiology 2005 55 6 1801 1811 2-s2.0-15944376926 10.1111/j.1365-2958.2005. 04504.x (Pubitemid 40445214)
29. Diplock A. T., Symons M. C. R., Rice-Evans C. A., Techniques in Free Radical Research 1991 Tokyo, Japan Elsevier Science
30. Ellman G. L., Tissue sulfhydryl groups. Archives of Biochemistry and Biophysics 1959 82 1 70 77 2-s2.0-3042934967
31. Aebi H., Catalase in vitro. Methods in Enzymology 1984 105 121 126 2-s2.0-0021318441 10.1016/S0076-6879(84)05016-3
32. Marklund S., Marklund G., Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. European Journal of Biochemistry 1974 47 3 469 474 2-s2.0-0016272750
33. Drabkin D. L., Spectrophotometric studies; the crystallographic and optical properties of the hemoglobin of man in comparison with those of other species. Journal of Biological Chemistry 1946 164 703 723
34. Jensen P. Ø., Lykkesfeldt J., Bjarnsholt T., Hougen H. P., Høiby N., Ciofu O., Poor antioxidant status exacerbates oxidative stress and inflammatory response to Pseudomonas aeruginosa lung infection in guinea pigs. Basic and Clinical Pharmacology and Toxicology 2012 110 4 353 358 2-s2.0-84858616134 10.1111/j.1742-7843.2011.00822.x
35. Ciofu O., Riis B., Pressler T., Poulsen H. E., Høiby N., Occurrence of hypermutable Pseudomonas aeruginosa in cystic fibrosis patients is associated with the oxidative stress caused by chronic lung inflammation. Antimicrobial Agents and Chemotherapy 2005 49 6 2276 2282 2-s2.0-19544386997 10.1128/AAC.49.6.2276-2282.2005 (Pubitemid 40734454)
36. Winklhofer-Roob B. M., Oxygen free radicals and antioxidants in cystic fibrosis: the concept of an oxidant-antioxidant imbalance. Acta Paediatrica 1994 83 395 49 57 2-s2.0-0028213618 (Pubitemid 24138152)
37. Galli F., Battistoni A., Gambari R., Pompella A., Bragonzi A., Pilolli F., Iuliano L., Piroddi M., Dechecchi M. C., Cabrini G., Oxidative stress and antioxidant therapy in cystic fibrosis. Biochimica et Biophysica Acta 2012 1822 5 690 713 2-s2.0-84858294319 10.1016/j.bbadis.2011.12.012
38. Brown R. K., Wyatt H., Price J. F., Kelly F. J., Pulmonary dysfunction in cystic fibrosis is associated with oxidative stress. European Respiratory Journal 1996 9 2 334 339 2-s2.0-0030042127 10.1183/09031936.96.09020334 (Pubitemid 26068628)
39. Winterbourn C. C., Bonham M. J. D., Buss H., Abu-Zidan F. M., Windsor J. A., Elevated protein carbonyls as plasma markers of oxidative stress in acute pancreatitis. Pancreatology 2003 3 5 375 382 2-s2.0-0242573337 10.1159/000073652 (Pubitemid 37409865)
40. Feuillet-Fieux M.-N., Nguyen-Khoa T., Loriot M.-A., Kelly M., de Villartay P., Sermet I., Verrier P., Bonnefont J.-P., Beaune P., Lenoir G., Lacour B., Glutathione S-transferases related to P. aeruginosa lung infection in cystic fibrosis children: preliminary study. Clinical Biochemistry 2009 42 1-2 57 63 2-s2.0-57649106997 10.1016/j.clinbiochem.2008.09.116
41. Satoh T., McKercher S. R., Lipton S. A., Nrf2/ARE-mediated antioxidant actions of pro-electrophilic drugs. Free Radical Biology and Medicine 2013 65 645 657
42. Xu Y., Duan C., Kuang Z., Pseudomonas aeruginosa pyocyanin activates Nrf2-ARE-mediated transcriptional response via the ROS-EGFR-PI3K-AKT/MEK-ERK MAP kinase signaling in pulmonary epithelial cells. PLoS ONE 2013 8 e72528
43. Michl R. K., Hentschel J., Fischer C., Reduced nasal nitric oxide production in cystic fibrosis patients with elevated systemic inflammation markers. PLoS ONE 2013 8 e79141
44. Fila L., Chladek J., Maly M., Nitrites and nitrates in exhaled breath condensate in cystic fibrosis: relation to clinical parameters. Bratislavske Lekarske Listy 2013 114 503 507
45. Thomas S. R., Kharitonov S. A., Scott S. F., Hodson M. E., Barnes P. J., Nasal and exhaled nitric oxide is reduced in adult patients with cystic fibrosis and does not correlate with cystic fibrosis genotype. Chest 2000 117 4 1085 1089 2-s2.0-0034090782 (Pubitemid 30228368)
46. Robroeks C. M., Rosias P. P. R., van Vliet D., Jöbsis Q., Yntema J.-B. L., Brackel H. J. L., Damoiseaux J. G. M. C., Den Hartog G. M., Wodzig W. K. W. H., Dompeling E., Biomarkers in exhaled breath condensate indicate presence and severity of cystic fibrosis in children. Pediatric Allergy and Immunology 2008 19 7 652 659 2-s2.0-54249153391 10.1111/j.1399-3038.2007.00693.x
47. de Winter-de Groot K. M., van Haren Noman S., Speleman L., Nasal nitric oxide levels and nasal polyposis in children and adolescents with cystic fibrosis. JAMA Otolaryngology 2013 139 931 936
48. Zhou M., Liu Y., Duan Y., Breath biomarkers in diagnosis of pulmonary diseases. Clinica Chimica Acta 2012 413 1770 1780
49. Ho L. P., Innes J. A., Greening A. R., Exhaled nitric oxide is not elevated in the inflammatory airways diseases of cystic fibrosis and bronchiectasis. European Respiratory Journal 1998 12 6 1290 1294 2-s2.0-0032422160 10.1183/09031936.98.12061290 (Pubitemid 29011417)
50. Walker W. T., Liew A., Harris A., Upper and lower airway nitric oxide levels in primary ciliary dyskinesia, cystic fibrosis and asthma. Respiratory Medicine 2013 107 380 386